Basgenbio is a clinico-genomic cohort-based R&D company with K-Biobank, which contains blood samples from 156,000subjects, along with their clinical and lifestyle information, with a maximum follow-up period of 18years. Notably, we have 8,662 cancer and 75,424 major chronic disease events.

Drawing on our experience in building an exclusive cohort data, Basgenbio also work on establishing a sarcopenia cohort and a rare disease biobank in collaboration with pharmaceutical companies, universities, and national associations.

Basgenbio also conducts clinical trial simulations with AI-based bioinformatics aiming at increasing the efficiency of drug development. It involves drug repurposing, drug combination, and the identification and validation of drug targets.

Basgenbio has exclusively accumulated imaging, clinical, and lifestyle data from five specialized spine and joint hospitals in South Korea. Specifically, among the imaging data, there are over 10.5 million X-ray images, over 690,000 MRI images, and among the clinical data, there are more than 26 million instances of prescription data and over 15.5 million instances of lab test data that have been established.

Through the integration of imaging data and omics data, we develop a solution and it will evolve into a comprehensive care platform for musculoskeletal disorders covering prevention, diagnosis, treatment planning, and prognosis prediction.